ATNF
vs
S&P 500
ATNF
S&P 500
Over the past 12 months, ATNF has significantly outperformed S&P 500, delivering a return of +803% compared to the S&P 500's +15% growth.
Stocks Performance
ATNF vs S&P 500
Performance Gap
ATNF vs S&P 500
Performance By Year
ATNF vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
180 Life Sciences Corp
Glance View
180 Life Sciences Corp. develops pharmaceuticals for chronic pain and inflammatory diseases. The company is headquartered in Menlo Park, California and currently employs 7 full-time employees. The company went IPO on 2017-06-07. The firm is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by research and combination therapy. The Company’s programs developing novel drugs for treating distinct inflammatory diseases. The firm has three product development platforms Anti-TNF platform, SCAs platform and α7nAChR platform. The Anti-TNF platform is focused on the fibrosis and anti-tumor necrosis factor (anti-TNF). The SCAs platform is focused on the drugs that are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). The α7nAChR platform, which is focused on the alpha 7 nicotinic acetylcholine receptor (α7nAChR). The firm is conducting clinical trials only for certain indications under the anti-TNF platform. The firm is also undertaking preclinical research and development activities for the SCA and the α7nAChR platforms.
